CollPlant Biotechnologies Ltd Ordinary Shares (CLGN)

FairStock Score: 49/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn good returns on capital and have a durable edge. CollPlant has an interesting proprietary recombinant human collagen platform and 3D bioprinting work, but the operating record in front of me is not that of a healthy business. In fiscal Q2 2026, revenue was just $108,000 while net income was -$2.7 million, a margin of -2524.07%. Trailing free cash flow was -$11.3 million against a $5.3 million market cap at the 2026-10-26 close, so the cash burn is enormous relative to the equity value. FairStock's calculations show a -211.5% FCF yield, a Piotroski F-score of 2/9, an Altman Z-score of -25.62, and a -0.36 P/E; those are signs of financial stress, not a margin of safety. The balance sheet has D/E of 0.54, which is not extreme by itself, but losses of this size can change that quickly. The provided growth figures are deeply negative, and the Lynch category is none because there are only 0 years of filed results when three are needed. On valuation, P/B of 1.11 may look modest, but book value is not earning power, and ROE of -151.99% shows the assets are not producing profits. The one thing I would watch is whether the proprietary collagen technology can move from promise to commercial revenue. Until then, this is a speculative biotech with a weak financial profile, not a Graham-style bargain.

In plain English: CollPlant is a small healthcare company that uses human collagen for tissue repair, 3D bioprinting and aesthetic medicine. The business looks weak today: in fiscal Q2 2026 it had only $108,000 of revenue and a $2.7 million net loss, and it is burning cash. At $3.75, the shares are not clearly cheap on current business results because there are no profits to anchor the price.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer